Frailty

Animal Biosciences Announces New Canine Clinical Research Evaluating Reversal of Age-Related Signs in Dogs

Retrieved on: 
Tuesday, March 5, 2024

Animal Biosciences, Inc. , a company aiming to extend the lifespan of pets, today announced new clinical research published to the preprint server BioRxiv that tested the effects of their “LeapYears” supplement designed to extend healthspan in dogs.

Key Points: 
  • Animal Biosciences, Inc. , a company aiming to extend the lifespan of pets, today announced new clinical research published to the preprint server BioRxiv that tested the effects of their “LeapYears” supplement designed to extend healthspan in dogs.
  • After five years of development and testing in dogs, leveraging discoveries made at Harvard Medical School, the study shows the first clinical evidence that it is possible to reverse age-related decline in dogs.
  • "The outcomes of the clinical trial, especially the enhancements in cognition, are encouraging and represent a unique achievement,” Dr. Olby noted.
  • In senior dogs, as in humans, this age-related decline can manifest as cognitive decline, increased frailty and lower engagement.

Canada signs $733 million bilateral agreement to help British Columbians age with dignity

Retrieved on: 
Monday, February 12, 2024

VANCOUVER, BC, Feb. 12, 2024 /CNW/ - Every senior in Canada deserves to age in dignity, safety, and comfort, regardless of where they live.

Key Points: 
  • VANCOUVER, BC, Feb. 12, 2024 /CNW/ - Every senior in Canada deserves to age in dignity, safety, and comfort, regardless of where they live.
  • Today, the Honourable Mark Holland, Canada's Minister of Health and the Honourable Adrian Dix, Minister of Health of British Columbia announced a bilateral agreement to invest $733 million over the next five years to help British Columbians age with dignity, closer to home, through improved access to home and community care and long-term care (LTC).
  • This funding builds on the $1.2 billion bilateral agreement that was announced with the province in October of 2023.
  • Progress on these initiatives and broader commitments will be measured against targets which British Columbia will publicly report on annually.

Veru Reports Fiscal 2024 First Quarter Financial Highlights

Retrieved on: 
Thursday, February 8, 2024

MIAMI, FL, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for potentially higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced financial highlights for its fiscal 2024 first quarter and provided a business update.

Key Points: 
  • The clinical study is expected to begin in April 2024 with the topline clinical results from the trial expected in the end of the fourth calendar quarter of 2024.
  • To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call.
  • An archived version of the audio webcast will be available for replay on the Company’s website for approximately three months.
  • A telephonic replay will be available on February 8, 2024 at approximately 12:00 p.m.

Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

Retrieved on: 
Tuesday, February 6, 2024

MIAMI, FL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for potentially higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for its Phase 2b clinical study to evaluate enobosarm, an oral novel selective androgen receptor modulator (SARM), to preserve muscle mass and physical function and further increase fat loss in patients receiving a Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drug for potentially higher quality weight loss.

Key Points: 
  • GLP-1 RA drugs are very effective drugs that result in significant weight loss.
  • Unfortunately, studies have shown that up to 50% of the total weight loss comes from muscle which is problematic as muscle is essential for metabolism, strength, and physical function.
  • The primary endpoint is lean body mass (muscle), and the key secondary endpoint is total body fat mass at 16 weeks.
  • The results of the separate Phase 2b open label extension clinical study is expected in calendar Q2 2025.

Blue California completes groundbreaking human clinical trial on ErgoActive® ergothioneine intervention for cognitive function, memory, and sleep

Retrieved on: 
Monday, February 5, 2024

Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Blue California , an industry leader in science-driven ingredient development, announced the successful completion of a groundbreaking human clinical trial of ergothioneine.

Key Points: 
  • Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Blue California , an industry leader in science-driven ingredient development, announced the successful completion of a groundbreaking human clinical trial of ergothioneine.
  • A double-blinded placebo-controlled clinical trial sponsored by Blue California has shown that ErgoActive® ergothioneine supports aspects of cognitive function, memory, and sleep in healthy elderly subjects with subjective memory complaints.
  • "Blue California is proud to have sponsored such an important human study,” said Linda May-Zhang, Ph.D., VP of Science and Innovation at Blue California.
  • Today, Blue California has made a substantial advancement by sponsoring a double-blinded, placebo-controlled clinical study conducted at a national research institution.

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

Retrieved on: 
Monday, January 8, 2024

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs are very effective drugs that result in significant weight loss.

Key Points: 
  • Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs are very effective drugs that result in significant weight loss.
  • Unfortunately, up to 50% of the total weight loss comes from muscle which is problematic as muscle is necessary for metabolism, strength, and physical function.
  • According to the CDC, 41.5% of older U.S. adults have obesity and could benefit from a weight loss medication.
  • Patients with critically low muscle mass may experience muscle weakness leading to poor balance, decreased gait speed, mobility disability, loss of independence, falls, bone fractures and increased mortality.

Keros Therapeutics to Develop KER-065 for the Treatment of Obesity

Retrieved on: 
Wednesday, January 3, 2024

“Obesity is a complex and chronic disease associated with numerous comorbidities and a growing prevalence in patients.

Key Points: 
  • “Obesity is a complex and chronic disease associated with numerous comorbidities and a growing prevalence in patients.
  • We believe there is a need for additional treatment options, including one that leads to weight loss without an associated loss of muscle and a potential for frailty.
  • RKER-065 and RKER-034 had equivalent increases in skeletal muscle in the diet-induced obesity (“DIO”) mouse model.
  • Based on this preclinical data, Keros believes that KER-065 has the potential to treat obesity both as a monotherapy and in combination with GLP-1 RA by increasing muscle mass and decreasing fat mass.

Home Healthcare Market to Value USD 786.85 Billion by 2032 | Precedence Research

Retrieved on: 
Thursday, November 23, 2023

Smart Healthcare Products Market : The global market size is expected to be worth around USD 427.43 billion by 2032 from USD 142 billion in 2022 with a CAGR of 11.7% over the forecast period 2023 to 2032.

Key Points: 
  • Smart Healthcare Products Market : The global market size is expected to be worth around USD 427.43 billion by 2032 from USD 142 billion in 2022 with a CAGR of 11.7% over the forecast period 2023 to 2032.
  • Digital Health Market : The global market size was valued at USD 262.63 billion in 2022 and it is anticipated to surpass around USD 939.54 billion by 2032 with a CAGR of 13.1% from 2023 to 2032.
    eHealth Market : The global market size was valued at US$ 128.99 billion in 2022 and is expected to hit US$ 707.23 billion by 2032, poised to grow at a CAGR of 18.6% from 2023 to 2032.
    mHealth Market : The global market was valued at USD 80.61 billion in 2022 and is expected to reach over USD 269.31 billion by 2032 with a registered CAGR of 12.3% from 2023 to 2032.
  • Healthcare IT Market : The global market was estimated at USD 200 billion in 2022 and is expected to hit around USD 1069.13 billion by 2032, poised to grow at a CAGR of 18.30% from 2023 to 2032.
  • Electronic Health Records Market : The global electronic health records market was estimated at USD 25 billion in 2022 and is expected to hit around USD 39.38 billion by 2032, poised to grow at a CAGR of 4.70% from 2023 to 2032.

Home Healthcare Market to Value USD 786.85 Billion by 2032 | Precedence Research

Retrieved on: 
Thursday, November 23, 2023

Smart Healthcare Products Market : The global market size is expected to be worth around USD 427.43 billion by 2032 from USD 142 billion in 2022 with a CAGR of 11.7% over the forecast period 2023 to 2032.

Key Points: 
  • Smart Healthcare Products Market : The global market size is expected to be worth around USD 427.43 billion by 2032 from USD 142 billion in 2022 with a CAGR of 11.7% over the forecast period 2023 to 2032.
  • Digital Health Market : The global market size was valued at USD 262.63 billion in 2022 and it is anticipated to surpass around USD 939.54 billion by 2032 with a CAGR of 13.1% from 2023 to 2032.
    eHealth Market : The global market size was valued at US$ 128.99 billion in 2022 and is expected to hit US$ 707.23 billion by 2032, poised to grow at a CAGR of 18.6% from 2023 to 2032.
    mHealth Market : The global market was valued at USD 80.61 billion in 2022 and is expected to reach over USD 269.31 billion by 2032 with a registered CAGR of 12.3% from 2023 to 2032.
  • Healthcare IT Market : The global market was estimated at USD 200 billion in 2022 and is expected to hit around USD 1069.13 billion by 2032, poised to grow at a CAGR of 18.30% from 2023 to 2032.
  • Electronic Health Records Market : The global electronic health records market was estimated at USD 25 billion in 2022 and is expected to hit around USD 39.38 billion by 2032, poised to grow at a CAGR of 4.70% from 2023 to 2032.

HEALTH RESEARCH FOUNDATION ANNOUNCES THE RECIPIENTS OF TWO HEALTH RESEARCH AWARDS

Retrieved on: 
Thursday, November 16, 2023

He pioneered a way to summarize an older adult's overall health status by counting health deficits in a frailty index which is commonly known as the Rockwood model of frailty.

Key Points: 
  • He pioneered a way to summarize an older adult's overall health status by counting health deficits in a frailty index which is commonly known as the Rockwood model of frailty.
  • Dr. Salami has been involved in over 85 research projects, totalling over $230 million, on various topics, including African immigrant child health, immigrant mental health, and access to healthcare for immigrant children.
  • The Diversity and Equity Research Award recognizes excellence in research by outstanding individuals whose work advances equitable participation in health research and access to health care in Canada and improves the well-being of all residents, particularly those facing inequities.
  • To learn more and stay up to date on Canadian health research, follow the HRF on Twitter and LinkedIn .